Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation aims to highlight the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI(TM) platform.
This announcement matters because it addresses a critical challenge in drug delivery: the intravenous administration of water-insoluble drugs. Many promising therapeutics are poorly soluble, limiting their clinical use. The Deciparticle platform's ability to form sub-20 nanometer particles could significantly expand the range of drugs that can be effectively delivered intravenously, potentially improving treatment options for cancer and other diseases. For the industry, this represents a step forward in nanomedicine, offering a new approach to enhance therapeutic index and unlock new clinical potential for established and novel therapeutics.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology.
The BIO International Convention is a major industry event, and the presentation of the Deciparticle platform there underscores its potential significance. For investors and stakeholders, the progress of Sapu006 and Sapu003 into Phase 1b trials signals that these programs are advancing toward clinical validation. The integration of AI through the PDAOAI platform also suggests a commitment to modernizing drug development processes, which could lead to more efficient identification of effective formulations and biomarkers.
In addition to its directly owned and developed drug pipeline, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
For more information on the full press release, visit https://ibn.fm/RUG7m. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
